Astellas Pharma ADR (ALPMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 12-2024 | 09-2024 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,135,659 | 1,323,321 | 623,870 | -193,492 | 596,581 |
| Depreciation Amortization | 937,521 | 646,666 | 329,848 | 999,563 | 671,910 |
| Accounts receivable | -637,013 | -414,011 | -281,458 | -632,260 | -295,852 |
| Accounts payable and accrued liabilities | -32,637 | -56,977 | -58,450 | -16,850 | -135,950 |
| Other Working Capital | -1,273,298 | -838,719 | -614,424 | -1,370,965 | -881,814 |
| Other Operating Activity | 1,188,779 | 1,261,393 | 378,989 | 1,830,688 | 563,778 |
| Operating Cash Flow | $2,319,011 | $1,921,673 | $378,375 | $616,684 | $518,654 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -267,287 | -178,459 | -88,375 | -180,206 | -198,307 |
| Purchase Sale Intangibles | -160,180 | -154,516 | -20,562 | -112,510 | -71,529 |
| Other Investing Activity | -31,584 | -26,901 | -27,165 | -390,390 | -175,098 |
| Investing Cash Flow | $-298,870 | $-205,360 | $-115,541 | $-570,596 | $-373,404 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -294,444 | -445,502 | 452,840 | N/A | -1,071,591 |
| Debt Issued | N/A | N/A | N/A | 161,218 | 1,340,000 |
| Debt Repayment | -405,568 | -173,407 | -46,002 | -215,853 | -174,448 |
| Common Stock Repurchased | -4,745 | -4,950 | -5,016 | -45,929 | -46,619 |
| Dividend Paid | -884,644 | -450,439 | -457,063 | -851,354 | -420,485 |
| Other Financing Activity | -13,716 | 14,940 | -20,948 | -173,745 | -70,793 |
| Financing Cash Flow | $-1,603,115 | $-1,059,358 | $-76,190 | $-1,125,663 | $-443,935 |
| Exchange Rate Effect | 11,479 | 14,083 | -159 | 51,157 | 12,636 |
| Beginning Cash Position | 1,224,418 | 1,280,930 | 1,299,767 | 2,215,534 | 2,249,103 |
| End Cash Position | 1,652,924 | 1,951,967 | 1,486,253 | 1,187,109 | 1,963,053 |
| Net Cash Flow | $428,506 | $671,038 | $186,486 | $-1,028,419 | $-286,050 |
| Free Cash Flow | |||||
| Operating Cash Flow | 2,319,011 | 1,921,673 | 378,375 | 616,684 | 518,654 |
| Capital Expenditure | -267,287 | -178,459 | -88,375 | -180,206 | -198,307 |
| Free Cash Flow | 2,051,725 | 1,743,214 | 290,000 | 436,478 | 320,347 |